

## **Product** Data Sheet

Inhibitors

**Screening Libraries** 

**Proteins** 

Target: VEGFR

Pathway: Protein Tyrosine Kinase/RTK

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description

JNJ 17029259 is an orally active and selective VEGF-R2 kinase inhibitor. JNJ 17029259 inhibits VEGF-mediated signal transduction. JNJ 17029259 has anti-angiogenic activity<sup>[1][2]</sup>.

## **REFERENCES**

[1]. Mohammed S. I. Makki, et al. Fluorine Substituted 1,2,4-Triazinones as Potential Anti-HIV-1 and CDK2 Inhibitors. Journal of Chemistry. 2014. Article ID 430573.

[2]. Reuman M, et al. Scalable synthesis of the VEGF-R2 kinase inhibitor JNJ-17029259 using ultrasound-mediated addition of MeLi-CeCl3 to a nitrile. J Org Chem. 2008 Feb 1;73(3):1121-3.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 1 of 1